Oracle (NYSE:ORCL) CEO Sells 22,562 Shares

Key Points

• Oracle CEO Michael Sicilia sold 22,562 shares at an average price of $151.59, generating approximately $3.42 million. The Rule 10b5-1 transaction reduced his ownership by 10.98%, leaving him with 182,929 shares.
• Oracle shares fell 3.2% to $144.44, while the company’s latest quarterly results exceeded expectations with $1.92 in adjusted EPS and $19.34 billion in revenue, up 29.6% year over year.
• Oracle declared a quarterly dividend of $0.50 per share, equivalent to a 1.4% yield, and analysts maintain a “Moderate Buy” consensus with an average price target of $252.58.

Oracle Corporation (NYSE:ORCL - Get Free Report) CEO Michael Sicilia sold 22,562 shares of the company's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $151.59, for a total transaction of $3,420,173.58. Following the transaction, the chief executive officer owned 182,929 shares of the company's stock, valued at approximately $27,730,207.11. This represents a 10.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oracle Trading Down 3.2%

Shares of ORCL stock traded down $4.76 during trading hours on Wednesday, hitting $144.44. 22,584,953 shares of the company's stock traded hands, compared to its average volume of 30,638,724. The stock has a market cap of $436.75 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 1.06 and a beta of 1.74. The stock's 50 day simple moving average is $142.39 and its 200 day simple moving average is $160.34. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 1.89. Oracle Corporation has a 12 month low of $114.50 and a 12 month high of $322.54.

Oracle (NYSE:ORCL - Get Free Report) last issued its quarterly earnings results on Thursday, September 10th. The enterprise software provider reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.18. The company had revenue of $19.34 billion during the quarter, compared to analysts' expectations of $19.13 billion. Oracle had a return on equity of 48.85% and a net margin of 26.36%.The business's quarterly revenue was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.47 earnings per share. Oracle has set its Q2 2027 guidance at 1.850-1.930 EPS and its FY 2027 guidance at 8.100-8.100 EPS. On average, sell-side analysts anticipate that Oracle Corporation will post 6.67 EPS for the current year.

Oracle Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 23rd. Stockholders of record on Friday, October 9th will be paid a $0.50 dividend. The ex-dividend date is Friday, October 9th. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Oracle's payout ratio is currently 31.35%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ORCL. Scotiabank reduced their price target on shares of Oracle from $241.00 to $215.00 and set a "sector outperform" rating for the company in a report on Wednesday, September 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $284.00 target price on shares of Oracle in a research note on Friday, September 11th. DA Davidson reaffirmed a "buy" rating and issued a $225.00 target price on shares of Oracle in a research report on Friday, September 11th. Morgan Stanley upped their price target on Oracle from $207.00 to $210.00 and gave the stock an "equal weight" rating in a research note on Friday, September 4th. Finally, Piper Sandler increased their price target on Oracle from $210.00 to $225.00 and gave the stock an "overweight" rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, thirty have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $252.58.

Institutional Trading of Oracle

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Oracle during the fourth quarter valued at approximately $4,336,031,000. Bank of New York Mellon Corp purchased a new stake in Oracle during the 2nd quarter valued at $1,911,930,000. Capital Research Global Investors raised its stake in Oracle by 29.3% during the 4th quarter. Capital Research Global Investors now owns 30,137,126 shares of the enterprise software provider's stock valued at $5,874,070,000 after buying an additional 6,826,299 shares during the last quarter. Cardano Risk Management B.V. lifted its holdings in shares of Oracle by 882.3% during the 4th quarter. Cardano Risk Management B.V. now owns 4,991,010 shares of the enterprise software provider's stock valued at $972,798,000 after buying an additional 4,482,934 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Oracle during the 2nd quarter valued at $625,454,000. 42.44% of the stock is currently owned by institutional investors.

Key Stories Impacting Oracle

Here are the key news stories impacting Oracle this week:

• Positive Sentiment: Oracle expanded its Digital Assets Data Nexus, adding payment execution integrations, wallet and smart-contract controls, Swift Ledger integration, and AI-assisted risk oversight. The offering could help banks modernize digital-money operations and create additional demand for Oracle’s banking software. Oracle Expands Digital Assets Data Nexus
• Positive Sentiment: New Oracle Health initiatives apply AI to oncology electronic health records, revenue-cycle management, and life-sciences research. These products may strengthen Oracle’s position in healthcare technology and support longer-term recurring cloud revenue. Oracle Oncology EHR
• Positive Sentiment: Oracle is collaborating with the Buck Institute on aging research using Oracle Life Sciences Data Intelligence, while a Wipro partnership expands managed pharmacovigilance services. The deals support Oracle’s strategy of monetizing real-world healthcare data and specialized cloud workloads. Oracle and Buck Institute Collaboration
• Neutral Sentiment: Oracle’s reported 50,000-GPU deployment and relationship with AMD highlight strong AI infrastructure demand, but investors are still assessing whether the resulting revenue and returns can justify the required capital spending. AMD and Oracle GPU Deployment
• Negative Sentiment: Heavy debt issuance to fund data-center and AI expansion is reportedly carrying a 37-basis-point financing premium. Higher borrowing costs could pressure cash flow and reduce the near-term returns from Oracle’s cloud investments. Oracle AI Debt Financing Costs
• Negative Sentiment: Reports of more than 500 layoffs in Oracle’s cloud infrastructure division, including engineers and data-center support staff, raise questions about operating efficiency, workforce requirements, and execution during rapid expansion. Oracle Cloud Layoffs

Oracle Company Profile

Oracle Corporation is a global enterprise technology company that develops and provides database software, cloud infrastructure, business applications and related technology services. Its offerings help organizations manage data, run applications, support business operations and build technology environments across on-premises, hybrid and cloud-based settings.

The company's products include Oracle Database, MySQL, Java, Oracle Cloud Infrastructure and a broad portfolio of cloud applications for enterprise resource planning, financial management, human resources, supply chain management, customer experience and industry-specific operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.